Unknown

Dataset Information

A hospital lipid-lowering protocol improves 2-year clinical outcomes in patients with acute coronary syndrome.


ABSTRACT:

Background

Although mortality after acute coronary syndrome (ACS) has improved in the acute phase, cardiovascular events occur at a certain frequency in the chronic phase. A hospital lipid-lowering protocol (HLP) could be effective in providing optimal lipid-lowering therapy to improve long-term clinical outcomes after ACS.

Aims

This study investigated the impact of HLP on clinical outcomes in patients with ACS.

Methods

We retrospectively analysed 1,114 ACS patients who had undergone successful percutaneous coronary intervention between November 2011 and June 2021. In December 2018, we introduced a HLP that included the prescription of the maximum tolerated dose of statin, ezetimibe, and eicosapentaenoic acid after ACS treatment. We compared 2-year clinical outcomes b

SUBMITTER: Nakao S 

PROVIDER: S-EPMC11413639 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature